|
|
|
Volumn 26, Issue 3 SUPPL. 8, 1999, Pages 21-26
|
|
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE ANTIBIOTIC AGENT;
ANTINEOPLASTIC AGENT;
DOCETAXEL;
DOXORUBICIN;
EDATREXATE;
GEMCITABINE;
NAVELBINE;
PACLITAXEL;
ADVANCED CANCER;
ARTICLE;
BREAST CARCINOMA;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RESISTANCE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG METABOLISM;
HUMAN;
LEUKOPENIA;
LIVER METASTASIS;
METASTASIS;
METASTASIS INHIBITION;
MUCOSA INFLAMMATION;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
HUMANS;
NEOPLASM METASTASIS;
PACLITAXEL;
RANDOMIZED CONTROLLED TRIALS;
TAXOIDS;
|
|
EID: 0033010030
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (13)
|
|
References (41)
|
